References
- Lee BB, Simpson JM, Craig JC, Bhuta T. Methenamine hippurate for preventing urinary tract infections. Cochrane Database Syst. Rev. 4 CD003265 (2007).
- Leibovici L. Phenazopyridine. In: AHFS drug information 2004. McEvoy GK (Ed.). American Society of Health-System Pharmacists, Bethesda, MD, USA, 3413–3414 (2004).
- Walther H, Willoughby RM. Oral dye therapy in urogenital infections. Am. J. Surg. 25(3), 460–466 (1934).
- Gould S. Urinary tract disorders. Clinical comparison of flavoxate and phenazopyridine. Urology 5(5), 612–615 (1975).
- Trickett PC. Ancillary use of phenazopyridine (Pyridium) in urinary tract infections. Curr. Ther. Res. Clin. Exp. 12(7), 441–445 (1970).
- Anderson C, Chimhanda M, Sloan J, Galloway S, Sinacore J, Brubaker L. Phenazopyridine does not improve catheter discomfort following gynecologic surgery. Am. J. Obstet. Gynecol. 204(3), 267.e1–267.e3 (2011).
- Heifetz CL, Fisher MW. Phenazopyridine–sulfonamide combination antibacterial therapy in mice. Antimicrob. Agents Chemother. 3(1), 134–135 (1973).
- Marcelín-Jiménez G, Angeles AP, Martínez-Rossier L, Fernández SA. Ciprofloxacin bioavailability is enhanced by oral co-administration with phenazopyridine: a pharmacokinetic study in a Mexican population. Clin. Drug Investig. 26(6), 323–328 (2006).
- Aizawa N, Wyndaele JJ. Effects of phenazopyridine on rat bladder primary afferent activity, and comparison with lidocaine and acetaminophen. Neurourol. Urodyn. 29(8), 1445–1450 (2010).
- Yu CH, Wang CH, Chang CC. Chocolate-colored blood with normal artery oxygen: methemoglobinemia related to phenazopyridine. Am. J. Med. Sci. 341(4), 337 (2011).
- Haigh C, Dewar JC. Multiple adverse effects of pyridium: a case report. South. Med. J. 99(1), 90–92 (2006).
- Vega J. Acute renal failure caused by phenazopyridine. Rev. Med. Chil. 131(5), 541–544 (2003).
- Rivas R, Martínez Torres A, Bohorques R, Martínez Albelo I. Acute kidney failure caused by phenazopyridine overdose. Nefrologia 21(1), 97–98 (2001).
- Siddiqui MA. Chronic severe hemolytic anemia from phenazopyridine. Ann. Intern. Med. 122(2), 156–157 (1995).
- Thomas RJ, Doddabele S, Karnad AB. Chronic severe hemolytic anemia related to surreptitious phenazopyridine abuse. Ann. Intern. Med. 121(4), 308 (1994).
- Jeffery WH, Zelicoff AP, Hardy WR. Acquired methemoglobinemia and hemolytic anemia after usual doses of phenazopyridine. Drug Intell. Clin. Pharm. 16(2), 157–159 (1982).
- Phenazopyridine hydrochloride CAS No. 136-40-3. In: Report on Carcinogens (Volume 12). US Department of Health and Human Services, Washington, DC, USA, 341–342 (2011).
- Shi CW, Asch SM, Fielder E, Gelberg L, Nichol MB. Consumer knowledge of over-the-counter phenazopyridine. Ann. Fam. Med. 2(3), 240–244 (2004).
- Shi CW, Asch SM, Fielder E et al. Usage patterns of over-the-counter phenazopyridine (pyridium). J. Gen. Intern. Med. 18(4), 281–287 (2003).
- Gannon K. Rx-to-OTC switches could be mixed blessing for R.Ph.s. Drug Topics 134, 30–32 (1990).
- Blenkinsopp A, Bradley C. Over-the-counter drugs: patients, society, and the increase in self medication. BMJ 312, 629–632 (1996).
- Jacobs LR. Prescription to over-the-counter drug reclassification. Am. Fam. Physician 57(9), 2209–2214 (1998).
Websites
- Over-the-counter products; safety and efficacy review. In: Federal Register (Volume68). FDA, Silver Springs, MD, USA, 75585–75591 (2003). www.federalregister.gov
- Gilderman L, Hendry D, Patrick K. Evaluation of the efficacy of phenazopyridine Hydrochloride (Formula PD-F-0016) as a urinary analgesic in women with urinary tract infections. FDA’s Dockets Management. Protocol Number: 99-001-P (2001). www.fda.gov
- Linn ET. Phenazopyridine Monograph. University of New Mexico College of Pharmacy, 1–15 (2008). http://hsc.unm.edu
- Comments of Polymedica Pharmaceuticals on the request for data and information on over-the-counter use of phenazopyridine hydrochloride as a urinary tract analgesic. FDA’s Dockets Management. Docket No. 2003N-0539 (2004). www.fda.gov